YU19199A - Supstituisani tricikli - Google Patents

Supstituisani tricikli

Info

Publication number
YU19199A
YU19199A YU19199A YU19199A YU19199A YU 19199 A YU19199 A YU 19199A YU 19199 A YU19199 A YU 19199A YU 19199 A YU19199 A YU 19199A YU 19199 A YU19199 A YU 19199A
Authority
YU
Yugoslavia
Prior art keywords
phenyl
alkyl
radicals
heterocyclic radicals
conh2
Prior art date
Application number
YU19199A
Other languages
English (en)
Inventor
Benjamin Alan Anderson
Nicholas James Bach
Jolie Anne Bastian
Nancy Kay Harn
Richard Waltz Harper
Gary Alan Hite
Michael Dean Kinnick
Ho-Shen Lin
Richard James Loncharich
Iii John Mcneill Mcgill
Edward David Mihelich
John Michael Morin
Michael Leroy Phillips
Michael Enrico Richett
Daniel Jon Sall
Jason Scott Sawyer
Richard Walter Schevitz
Robert Theodore Vasileff
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU19199A publication Critical patent/YU19199A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na nova supstituisana triciklicna jedinjenja koja su pogodna za inhibiranje sPLA2 oslobodjenog iz masnih kiselina u uslovima kao sto je septicni sok, i koja se mogu predstaviti opstom formulom I: gde je: Z-cikloheksenil ili fenil, R20 se bira iz grupa (a), (b) i (c) gde je: (a) -(C5-C20) alkil, -(C5-C20) alkenil, -(C5-C20) alkinil, karbociklicni radikali, ili heterociklicni radikali ili clan od (a) supstituisan sa jednim ili vise nezavisno izabranih neintereagujucih supstituenata; ili je grupa -(L_-R80; gde, (L)-je dvovalentna vezujuca grupa od 1 ili 12 atoma izabranih od ugljenika, vodonika, kiseonika, azota, ili sumpora; gde je kombinacija atoma u -(L) izabrana iz grupe koja se sastoji od (i) ugljenika i vodonika jedino, (ii) samo jednog sumpora, (iii) samo jednog kiseonika, (iv) jedino od jednog ili dva azota i vodonika, (v) samo od ugljenika, vodonika, i jednog sumpora, i (vi) samo od ugljenika, vodonika i kiseonika; i gde je R80 grupa izabrana iz (a) ili (b); R21 je jedan od neintereagujucih supstituenata gde je f od 1-3; R1 je -NHNH2, -NH2, ili -CONH2; R2 se bira iz grupa koje sadrze -OH, i -O(CH2)tR5 gde R5 je H, -CN, -NH2, -CONH2, -CONR9R10, -NHSO2R15; -CONHSO2R15, gde R15 cini -(c1-C6) alkil ili -CF3; fenil ili fenil supstituisan sa -CO2H ili -CO2 -(C1-C4)alkil; i -(La)-kisela grupa, gde je -(La)- je kiselinsko povezivanje koje ima duzinu kiselinskog povezivanja od 1 do 7 i t je 1-5. R3 se bira od neintereagujucih supstituenata, karbociklicnih radikala, i heterociklicnih radikala supstituisanih sa neintereagujucim supstituentima; ili farmaceutski prihvatljivih racemata, solvata, tautomera, optickih izomera, prolekovitih derivata ili njihovih soli.
YU19199A 1998-04-17 1999-04-16 Supstituisani tricikli YU19199A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
YU19199A true YU19199A (sh) 2002-08-12

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
YU18999A YU18999A (sh) 1998-04-17 1999-04-16 Supstituisani tricikli
YU19199A YU19199A (sh) 1998-04-17 1999-04-16 Supstituisani tricikli

Family Applications Before (1)

Application Number Title Priority Date Filing Date
YU18999A YU18999A (sh) 1998-04-17 1999-04-16 Supstituisani tricikli

Country Status (30)

Country Link
EP (2) EP0950657B1 (sh)
JP (2) JPH11322713A (sh)
KR (2) KR19990083232A (sh)
CN (1) CN1149193C (sh)
AR (2) AR018186A1 (sh)
AT (2) ATE271037T1 (sh)
AU (2) AU753436B2 (sh)
BR (2) BR9902365A (sh)
CA (2) CA2269246C (sh)
CO (2) CO5011054A1 (sh)
CZ (2) CZ136999A3 (sh)
DE (2) DE69917833T2 (sh)
DK (1) DK0950657T3 (sh)
DZ (1) DZ2769A1 (sh)
EA (2) EA002816B1 (sh)
ES (2) ES2226286T3 (sh)
HU (2) HUP9901221A3 (sh)
ID (2) ID23287A (sh)
IL (2) IL129483A0 (sh)
NO (2) NO314400B1 (sh)
NZ (3) NZ335251A (sh)
PE (2) PE20000432A1 (sh)
PL (2) PL332566A1 (sh)
PT (1) PT950657E (sh)
SG (2) SG81977A1 (sh)
SI (1) SI0950657T1 (sh)
TR (2) TR199900853A3 (sh)
TW (1) TWI238160B (sh)
YU (2) YU18999A (sh)
ZA (2) ZA992771B (sh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009978A1 (en) * 1997-08-28 1999-03-04 Eli Lilly And Company Method for treatment of non-rheumatoid athritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
ATE350367T1 (de) * 1999-07-19 2007-01-15 Lilly Co Eli Spla2 inhibitoren
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
US20040102442A1 (en) * 2000-06-29 2004-05-27 Kohji Hanasaki Remedies for alzheimer's disease
US20040077651A1 (en) * 2000-06-29 2004-04-22 Kohji Hanasaki Remedies for cancer
WO2002000256A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cirrhosis
CA2413582A1 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
AU2002239263A1 (en) * 2000-12-18 2002-07-01 Eli Lilly And Company Tetracyclic carbazole derivates and their use as spla2 inhibitors
US6933313B2 (en) 2001-03-28 2005-08-23 Eli Lilly And Company Substituted carbazoles as inhibitors of sPLA2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
EP2256105B1 (en) 2008-03-26 2013-12-04 Daiichi Sankyo Company, Limited Novel tetrahydroisoquinoline derivative
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
US8580795B2 (en) 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
JP2012523424A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
EP2417115A4 (en) 2009-04-07 2012-10-31 Infinity Pharmaceuticals Inc FATTY ACID AMIDE HYDROLASE INHIBITORS
CA2788587C (en) 2010-02-03 2020-03-10 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
MX2015006871A (es) 2012-11-30 2015-09-16 Ge Healthcare Ltd Proceso de cristalizacion de derivados de indoles triciclicos.
CA2889642A1 (en) * 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
CA2240395A1 (en) * 1995-12-13 1997-06-19 David Kent Herron Naphthyl acetamides as spla2 inhibitors
IL129481A0 (en) * 1996-10-30 2000-02-29 Lilly Co Eli Substituted tricyclics
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
JP2001522884A (ja) * 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
TWI238160B (en) 2005-08-21
IL129485A0 (en) 2000-02-29
AU2381799A (en) 1999-10-28
NO991821D0 (no) 1999-04-16
EA002816B1 (ru) 2002-10-31
SG81976A1 (en) 2001-07-24
HU9901221A (hu) 2000-04-28
KR19990083233A (ko) 1999-11-25
CN1253948A (zh) 2000-05-24
ID23287A (id) 2000-04-05
HUP9901221A3 (en) 2001-11-28
EP0952149B1 (en) 2004-06-09
TR199900853A2 (xx) 1999-11-22
DK0950657T3 (da) 2004-11-22
PT950657E (pt) 2004-11-30
CA2269262A1 (en) 1999-10-17
IL129483A0 (en) 2000-02-29
YU18999A (sh) 2002-08-12
NO312240B1 (no) 2002-04-15
HU9901220A (hu) 2000-04-28
EP0952149A2 (en) 1999-10-27
PE20000432A1 (es) 2000-05-23
CO5011054A1 (es) 2001-02-28
HUP9901220A3 (en) 2001-11-28
CZ136999A3 (cs) 1999-11-17
EP0950657A2 (en) 1999-10-20
ZA992772B (en) 2002-07-16
NO991822L (no) 1999-10-18
AU753436B2 (en) 2002-10-17
CA2269246C (en) 2009-08-25
KR100586761B1 (ko) 2006-06-08
AU2381999A (en) 1999-10-28
BR9901279A (pt) 2000-05-02
BR9902365A (pt) 2001-04-24
DE69917833T2 (de) 2005-07-14
EA199900303A2 (ru) 1999-10-28
CN1149193C (zh) 2004-05-12
EA002347B1 (ru) 2002-04-25
ATE271037T1 (de) 2004-07-15
CA2269246A1 (en) 1999-10-17
NZ507564A (en) 2002-10-25
PL332566A1 (en) 1999-10-25
ES2226286T3 (es) 2005-03-16
JPH11322713A (ja) 1999-11-24
DE69917833D1 (de) 2004-07-15
HU9901221D0 (en) 1999-06-28
EP0950657A3 (en) 2001-08-16
EP0950657B1 (en) 2004-07-14
DE69918590D1 (de) 2004-08-19
EA199900301A2 (ru) 1999-10-28
TR199900853A3 (tr) 1999-11-22
NO991821L (no) 1999-10-18
ES2222663T3 (es) 2005-02-01
KR19990083232A (ko) 1999-11-25
SG81977A1 (en) 2001-07-24
EA199900301A3 (ru) 2000-04-24
PL332565A1 (en) 1999-10-25
TR199900843A2 (xx) 2000-02-21
DE69918590T2 (de) 2005-07-21
NO991822D0 (no) 1999-04-16
EA199900303A3 (ru) 2000-04-24
NZ335251A (en) 2000-11-24
EP0952149A3 (en) 2001-08-16
ATE268756T1 (de) 2004-06-15
NO314400B1 (no) 2003-03-17
ZA992771B (en) 2002-04-18
CZ137099A3 (cs) 1999-11-17
CO5031247A1 (es) 2001-04-27
AR018593A1 (es) 2001-11-28
AU753547B2 (en) 2002-10-24
SI0950657T1 (en) 2005-02-28
PE20000476A1 (es) 2000-06-02
HU9901220D0 (en) 1999-06-28
JP2000026416A (ja) 2000-01-25
ID23761A (id) 2000-05-11
DZ2769A1 (fr) 2003-12-01
JP4435330B2 (ja) 2010-03-17
NZ335253A (en) 2000-11-24
AR018186A1 (es) 2001-10-31

Similar Documents

Publication Publication Date Title
YU19199A (sh) Supstituisani tricikli
ES2095081T3 (es) Procedimiento para la preparacion de derivados de taxano.
ES2096328T3 (es) Nuevo procedimiento para la esterificacion de la bacatina iii y de la desacetil-10 bacatina iii.
AR018185A1 (es) Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2
ES2080922T3 (es) Derivados de la n-sulfonil-indolina, su preparacion, y las composiciones farmaceuticas que los contienen.
ATE203744T1 (de) Naphthyl-acetamide als spla2-inhibitoren
HU9401842D0 (en) Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophyl elastase
PT97766A (pt) Processo depreparacao de derivados de isocromano e de composicoes farmaceuticas que os contem
EP0518798A3 (en) Compositions for use in the treatment of aphtous ulcers and other mucocutaneous disorders
NZ219758A (en) Heterocyclic ester derivatives of 1,4 dihydropyridin-3,5-dicarboxylic acids intermediates and pharmaceutical compositions
DE68918832D1 (de) Benzoxazepinderivate.
PL437423A1 (pl) Nowe n-bromoalkilowe estry kwasu 4-chloro-2-fenoksyoctowego, sposób ich otrzymywania oraz ich zastosowanie
IE790013L (en) Polysubstituted-2-(3-loweralkylamino-2-or(1)-propoxy)¹pyridines
ES2082474T3 (es) Derivados de tetrahidrobenzazepina que inhiben la lipoxigenasa.
ES535569A0 (es) Procedimiento para preparar 11-piperazinil-5h-imidazo(2, 1-c) (1, 4) benzodiazepinas
ES2060095T3 (es) Nuevas imidazobenzodiazepinas y sus sales, procedimiento de preparacion, aplicacion como medicamentos y composiciones que los contienen.
GR3020336T3 (en) Substituted benzoate derivatives
KR950003256A (ko) 헵타노에이트 유도체
YU48336B (sh) Postupak za dobijanje 6,7-dihloro-1,5-dihidroimadazo/2,1-b/hinazolin-2/3h/on